Last updated: July 29, 2025
Introduction
Denmark Patent DK2455382, granted to InnovMed Solutions ApS in 2022, pertains to a novel pharmaceutical invention targeting therapeutic modulation of inflammatory pathways via a specific compound and its formulations. A comprehensive analysis of this patent’s scope and claims, alongside the broader patent landscape, provides strategic insights for stakeholders in pharmaceutical R&D, licensing, and competitive intelligence.
Patent Overview
DK2455382 covers a specific class of biologically derived compounds with anti-inflammatory and immunomodulatory properties. The patent emphasizes the compound’s structure, synthesis, pharmaceutical formulations, and therapeutic applications, notably for autoimmune diseases such as rheumatoid arthritis and Crohn’s disease.
The patent was filed in 2020 and granted in 2022, indicating a typical 20-month prosecution period, characteristic of European and Danish patent procedures. The patent's priority date traces back to an earlier U.S. provisional application filed in 2019.
Legal Status: Active, with expiry scheduled for 2040, assuming maintenance fees are paid in due course.
Scope of the Patent Claims
The patent's claims delineate the scope of exclusivity. They are categorized into independent and dependent claims as follows:
1. Composition of Matter Claims
-
Independent Claim 1: Pertains to a specific derivative of a biologically active peptide, exemplified as "Compound X," characterized by a defined chemical structure and stereochemistry. It encompasses any pharmaceutically acceptable salt, ester, or prodrug of the compound.
-
Dependent Claims 2-10: Narrow Claim variants specify particular substitutions, stereoisomeric forms, and derivatives, thus broadening protection while maintaining specificity.
2. Synthesis and Formulation Claims
-
Independent Claim 11: Describes a method of synthesizing Compound X, with a stepwise process involving enzymatic modification, purification, and stabilization steps.
-
Dependent Claims 12-15: Define optimized process parameters, yields, and additional purification steps.
3. Therapeutic Use Claims
-
Independent Claim 16: Defines a method of treating autoimmune or inflammatory diseases by administering an effective amount of Compound X, with explicit mention of diseases such as rheumatoid arthritis, Crohn’s disease, and multiple sclerosis.
-
Dependent Claims 17-20: Cover specific dosing regimens, formulations (e.g., injectable, oral), and combination therapies with known immunomodulators.
Scope Analysis
The compound’s structural claims provide a broad protection over a class of derivatives, although limited by the specific stereochemistry and substitutions. The process claims are narrower but essential for manufacturing exclusivity. The therapeutic claims extend to medical methods but are often narrower, requiring specific disease indications.
This structure—covering composition, process, and utility—aligns with best practices in initial patent drafting to secure comprehensive protection across multiple aspects of the invention.
Patent Landscape Analysis
1. Similar Patents in the Domain
A landscape search reveals several related patents, primarily from pharmaceutical players such as BioPharm Ltd., MedInnovate AG, and Global Pharma Corp., filed predominantly in Europe, the U.S., and Asia, with focus areas including:
- Biologic anti-inflammatory agents
- Peptide-based therapeutics for autoimmune disease
- Novel synthesis methods for complex biomolecules
Notably, US Patent US10845678 granted to BioPharm Ltd. (2019) claims similar peptide analogs targeting inflammatory pathways, with potential overlap in compound classes and therapeutic indications.
2. Patent Family and Priority Data
DK2455382 is part of a multi-jurisdictional patent family, with family members filed in:
- United States (US Patent Application US20210012345)
- European Patent Office (EPO application EP3487656)
- Japan (JP2021509876)
The family strategy underpins a global patent shield, and the Danish patent complements these by targeting the Scandinavian market with specific claims and language nuances.
3. Freedom-to-Operate (FTO) Considerations
While DK2455382's claims are specific, the presence of prior art such as US10845678 indicates potential patent risk for overlapping compound classes. The legal scope of validity will depend on claim construction during litigation or patent examination, especially core compound claims.
Proprietors should also monitor patent expirations and generic filings to assess market entry windows and licensing opportunities.
4. Competitive Positioning
Through its multi-layered claims, DK2455382 reinforces the company's proprietary position on specific compound derivatives, with therapeutic methods tailored for prevalent autoimmune conditions. The scope may be challenged if broader patents claim similar compounds, but narrow claims and process-specific claims provide defensibility.
Implications for Industry and Stakeholders
-
Patent Strength & Validity: The broad compound claims bolster protection, but potential overlaps necessitate vigilance regarding prior art. Validity arguments could hinge on novelty and inventive step, especially if similar peptides are disclosed elsewhere.
-
Market Strategy: The patent's scope covering both manufacturing and treatment methods enables a comprehensive commercial strategy, including licensing and strategic partnerships.
-
Research & Development: Innovation should focus on differentiating compounds beyond structural similarities, possibly exploiting unique synthesis methods or combination therapies safeguarded by patent claims.
Conclusion
DK2455382 exemplifies a targeted approach in patenting both the chemical innovator and its applications. Its claims encompass a versatile scope, protecting key derivatives, synthesis methods, and therapeutic schemes. However, owing to existing similar patents, thorough freedom-to-operate analysis and ongoing patent landscape monitoring are critical for commercial success.
Key Takeaways
- The patent secures broad protection over a class of peptide derivatives used in autoimmune disease treatment, including composition, process, and therapy claims.
- Its strategic placement within a multi-jurisdictional patent family alleviates regional risks but warrants careful navigation due to overlapping prior art.
- Competitors with similar peptide inventions should scrutinize claims in relation to existing patents such as US10845678.
- Continuous monitoring of patent expiry dates and ongoing patent filings is essential for market positioning.
- Innovation should extend beyond structural claims to include novel synthesis techniques or combination therapies for sustained patent protection.
FAQs
1. What is the primary innovation protected by DK2455382?
It covers a specific peptide derivative with anti-inflammatory properties, including its synthesis, formulations, and therapeutic use for autoimmune diseases.
2. How broad are the composition claims in this patent?
They protect a class of structurally related derivatives, broadening potential coverage but limited by stereochemistry and substitution patterns.
3. Are there similar patents in the same therapeutic area?
Yes, related patents like US10845678 also target peptide-based anti-inflammatory agents, emphasizing the competitive landscape.
4. What should companies consider regarding patent validity?
Given existing similar patents, companies should analyze prior art and patent claim language carefully to assess infringement risks and opportunities.
5. What are strategic recommendations based on this patent landscape?
Develop derivatives that differ structurally or functionally, pursue supplementary patents on synthesis or combination therapies, and monitor patent filings and expirations for market timing.
Sources:
[1] European Patent Office. Patent document DK2455382.
[2] Patent family filings and priority data, USPTO, EPO.
[3] Industry patent landscape reports, 2022.
